How the gut hormones GIP and GLP-1 change whole‑body glucose use and organ blood flow

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a mechanistic imaging study using a total‑body PET‑CT scanner to measure dynamic uptake of the glucose analogue 18F‑FDG and blood flow with H2¹⁵O during controlled hyperglycemia and raised endogenous insulin. The project has two sub‑studies: one where healthy volunteers receive separate infusions of GIP, GLP‑1, or saline during a hyperglycemic clamp with FDG PET‑CT to quantify skeletal muscle glucose uptake, and a second including healthy controls and people with type 2 diabetes who receive saline and either GIP or GLP‑1 with repeated H2¹⁵O PET‑CT to measure organ perfusion. Each participant attends multiple experimental visits with hormone or placebo infusions and PET imaging to compare effects across organs. Results will quantify hormone‑specific effects on tissue glucose handling and blood flow.

Why it matters

Who can join: the full rules

Sub-study 1 (Healthy individuals):

* Age 23-50 years
* BMI 20.0-26.9 kg/m²
* HbA1c \< 42 mmol/mol
* Able to provide informed consent

Sub-study 2 - Participants with Type 2 Diabetes:

* Age 23-60 years
* Diagnosed with type 2 diabetes for ≥3 months
* HbA1c \> 53 mmol/mol
* Treatment with metformin only
* Able to provide informed consent

Sub-study 2 - Healthy control participants:

* Age 23-64 years
* HbA1c \< 42 mmol/mol
* Able to provide informed consent

Exclusion Criteria (applies to all participants unless otherwise specified):

* Anaemia (haemoglobin below normal range)
* ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder
* Kidney disease (creatinine above normal range)
* Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)
* For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol
* Use of glucose-lowering medications other than metformin (Sub-study 2 only)
* Chronic obstructive pulmonary disease (Sub-study 2 only)
* Regular tobacco smoking or use of nicotine-containing products
* Claustrophobia
* Pregnancy, breastfeeding, or intention to become pregnant during the study period
* Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study
* Any medication or physical/psychological condition that may interfere with participation (per investigator judgement)
* Inability to speak or read Danish

Where it's running

• Copenhagen University Hospital - Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Mathilde Borring Brogaard, Doctor
• Email: mathilde.borring.brogaard@regionh.dk
• Phone: +4535454498

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.